AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib missed the co-primary endpoints in the double=blind, international Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, Imbruvica plus chemotherapy failed to significantly improve progression-free survival (PFS) or overall survival (OS) vs. placebo plus chemotherapy.

Full data from the trial will be submitted for presentation at a scientific meeting. AbbVie did not respond to inquiries regarding next steps for Imbruvica in the indication...